A Multicentre, Prospective Post-Marketing Observational Study To Evaluate The Effectiveness And Safety Of Clarithromycin 500 Mg ER In Upper Respiratory Tract Infection - NI

Abbott Healthcare Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•1 Male and female patients 18 to 65 years of age
•2 Newly diagnosed patients with onset of symptoms in previous 7 days with acute URTI (acute bacterial sinusitis, acute pharyngotonsillitis or acute otitis media) in the designated clinics as part of routine clinical care
•3 Patients prescribed to start clarithromycin 500 mg ER tablets once daily, as part of routine clinical practice
•4 Patients willing and able to sign a patient authorisation form (PAF) prior to study participation

•Patients who had been diagnosed and treated for an acute infection within the previous 28 days of study enrolment.
•Patients who may require hospitalization or ventilator support for the present complaints.
•Patients with history of clarithromycin or other antibiotic use in the preceding 1 month of study enrolment.
•Patients diagnosed with LRTI as per Investigator discretion.
•Hypersensitivity to macrolides.
•Patients on concomitant medication like steroids or other antibiotics.
•Patients on any other contraindicated medication based on approved prescribing information.
•Patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including anti.
•Pregnant or lactating women.
•Patients with any other conditions or diseases that Investigator/ HCP considers as ineligible to enroll in the study based on approved prescribing information.

发起方